Evidence map›Paper›PMID 36426082›Full record

ArticleData in brief2022

Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.

Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, Wolfgang Boehmerle, Petra Huehnchen, Matthias Endres, Raphael Mohr, Annette Compter, Christian U Blank, Tim Hagenacker and 23 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Data in brief, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 6 countries.

Leonie Müller-JensenDepartment of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany.
Sarah ZieroldSERIO Side Effects Registry Immunooncology, Germany.
Judith M VersluisDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Wolfgang BoehmerleDepartment of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany.
Petra HuehnchenDepartment of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany.
Matthias EndresDepartment of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany.
Raphael MohrDepartment of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, , Augustenburger Platz 1, Berlin 13353, Germany.
Annette CompterDepartment of Neuro-Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Christian U BlankDepartment of Medical Oncology, Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Tim HagenackerDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, Hufelandstr. 55, Essen 45147, Germany.
Friedegund MeierDepartment of Dermatology, Skin Cancer Center at the University Cancer Center Dresden and National Center for Tumor Diseases, TU Dresden, University Hospital Carl Gustav Carus, Dresden, Germany.
Lydia ReinhardtDepartment of Dermatology, Skin Cancer Center at the University Cancer Center Dresden and National Center for Tumor Diseases, TU Dresden, University Hospital Carl Gustav Carus, Dresden, Germany.
Anja GesierichDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
Martin SalzmannDepartment of Dermatology and National Center for Tumor Diseases (NCT), Skin Cancer Center, University Hospital Heidelberg, Heidelberg, Germany.
Jessica C HasselDepartment of Dermatology and National Center for Tumor Diseases (NCT), Skin Cancer Center, University Hospital Heidelberg, Heidelberg, Germany.
Selma UgurelDepartment of Dermatology, Venerology und Allergology, University Hospital Essen, Essen, Germany.
Lisa ZimmerDepartment of Dermatology, Venerology und Allergology, University Hospital Essen, Essen, Germany.
Patricia BanksAndrew Love Cancer Centre, University Hospital Geelong, Geelong, Australia.
Lavinia SpainMedical Oncology Department, Peter MacCallum Cancer Center, Melbourne, Australia.
Jennifer A SoonMedical Oncology Department, Peter MacCallum Cancer Center, Melbourne, Australia.
Tomohiro EnokidaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan.
Makoto TaharaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan.
Katharina C KählerDepartment of Dermatology, Venerology and Allergology, University of Schleswig-Holstein Hospital, Campus Kiel, Germany.
Ruth Seggewiss-BernhardtDepartment of Hematology and Oncology, Sozialstiftung Bamberg, Bamberg, Germany.
Catriona HarveyMelanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
Georgina V LongMelanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
Florian SchöberlDepartment of Neurology, Ludwig-Maximilian Universität, Marchioninistraße 15, München 83177, Germany.
Louisa von BaumgartenDepartment of Neurology, Ludwig-Maximilian Universität, Marchioninistraße 15, München 83177, Germany.
Thomas HundsbergerDepartment of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Max SchlaakDepartment of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany.
Lars E FrenchDepartment of Dermatology and Allergy, University Hospital, Ludwig-Maximilian Universität Munich, Frauenlobstr. 9-11, München 80337, Germany.
Samuel KnaussDepartment of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany.
Lucie M HeinzerlingSERIO Side Effects Registry Immunooncology, Germany.
Freie Universität Berlin · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEThe Netherlands Cancer Institute · NLEssen University Hospital · DEHeidelberg University · DELudwig-Maximilians-Universität München · DENational Cancer Center Hospital East · JPPeter MacCallum Cancer Centre · AUCharité - Universitätsmedizin Berlin · DEGeelong Hospital · AUHumboldt-Universität zu Berlin · DEMelanoma Institute Australia · AUNational Center for Tumor Diseases · DESozialstiftung Bamberg · DEThe University of Sydney · AUUniversitätsklinikum Erlangen · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Carl Gustav Carus · DEUniversity of Lübeck · DEUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past decade, cancer immunotherapy with immune checkpoint inhibitors (ICIs) has significantly improved the outcome of many malignancies. However, with the broad use of ICIs, neurological immune related adverse events (irAE) are increasingly recognized. ICI-induced encephalitis (ICI-iE) is a particularly severe irAE, often leading to treatment termination, long-term sequalae or death. Despite its high morbidity and mortality, data on clinical features and diagnostic criteria are limited. We aimed to define clinical, radiologic and laboratory characteristics of ICI-iE and identify factors that discriminate it from anti-leucine-rich glioma-inactivated (anti-LGI)-1 encephalitis and herpes simplex virus (HSV)-1 encephalitis - two alternative causes of encephalitis - to increase the awareness of ICI-iE and improve its diagnosis and management. To that end, we retrospectively collected 30 cases of ICI-iE that were reported to the Side Effect Registry Immuno-Oncology (SERIO) and 46 cases of anti-LGI1 encephalitis or herpes simplex virus (HSV)-1 encephalitis that presented to a large German neurological referral center (Charité Universitätsmedizin Berlin) between January 2015 and September 2021. Signs and symptoms, imaging and electroencephalogram features, laboratory findings and outcome measures were assessed using standardized case report forms as well as patients' medical records and compared between the groups. The data reported here represents the largest primary cohort of patients with ICI-iE to date and the first comparison with other types of encephalitis. As all three disorders - ICI-iE, HSV-1 encephalitis and anti-LGI1 encephalitis - are rare neurological entities, this dataset can be used as a reference in future clinical studies on ICI-induced neurotoxicity, neurological autoimmune disorders, and central nervous system infections.

Indexed as

Anti-LGI1 encephalitisCancerEncephalitisHerpetic encephalitisImmune related adverse eventsImmunotherapyNeurotoxicity

Identifiers

PMID36426082
PMCPMC9679487
OpenAlexW4298148672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.